SMA Day: AveXis Gene Therapy Creeps Forward As Biogen Drug’s Sales Slow – Xconomy
Xconomy |
SMA Day: AveXis Gene Therapy Creeps Forward As Biogen Drug's Sales Slow
Xconomy Xconomy Boston —. Just a few years ago, there were no drugs available for patients with the rare genetic disease spinal muscular atrophy. Now two cutting edge therapies look headed for a commercial battle, with each data and revenue update a key … Novartis-bound AveXis posts early look at data from pivotal SMA gene therapy trial AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3 |
